Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CKS1B | P61024 | 1/20 | 0.52 |
| ▸ | SKP1 | P63208 | 1/20 | 0.52 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.52 |
| ▸ | SUV39H2 | Q9H5I1 | 10/20 | 0.47 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.47 |
| ▸ | BTK | Q06187 | 2/20 | 0.47 |
| ▸ | JAK3 | P52333 | 1/20 | 0.47 |
| ▸ | SYK | P43405 | 1/20 | 0.46 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.44 |
| ▸ | PIM1 | P11309 | 1/20 | 0.44 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.44 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.44 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.44 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.44 |
| ▸ | ITGAL | P20701 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12991335 | 0.91 | CKS1B (0.54) | CKS1BSKP1SKP2SUV39H2PDE10A | |
| SCHEMBL12991199 | 0.89 | CKS1B (0.52) | CKS1BSKP1SKP2SUV39H2PDE10A | |
| SCHEMBL12990834 | 0.86 | CKS1B (0.50) | CKS1BSKP1SKP2SUV39H2PDE10A | |
| SCHEMBL3528679 | 0.85 | CKS1B (0.61) | CKS1BSKP1SKP2SUV39H2PDE10A | |
| SCHEMBL12991183 | 0.83 | CKS1B (0.59) | CKS1BSKP1SKP2SUV39H2PDE10A | |
| SCHEMBL3534646 | 0.81 | CKS1B (0.56) | CKS1BSKP1SKP2SUV39H2PDE10A | |
| SCHEMBL7384523 | 0.80 | JAK3 (0.59) | CKS1BSKP1SKP2SUV39H2PDE10A | |
| SCHEMBL38666481 | 0.80 | JAK3 (0.59) | CKS1BSKP1SKP2SUV39H2PDE10A | |
| SCHEMBL38665065 | 0.80 | JAK3 (0.59) | CKS1BSKP1SKP2SUV39H2PDE10A | |
| SCHEMBL38663924 | 0.80 | JAK3 (0.59) | CKS1BSKP1SKP2SUV39H2PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7858786-B2 | Pyrimidines and pyrazines useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCOROPATED (US) | 2010-12-28 | — | — | US | disclosed |
| US-20070093454-A1 | Pyrimidines and pyrazines useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED | 2007-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093454-A1 | Pyrimidines and pyrazines useful as modulators of ion channels | KCNJ1, KCNJ2, KCNJ11 | CKS1B 2173/4885SKP1 1399/4885SKP2 1603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.